CAR T-CELL

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  

CAR T-CELL
Oct 11, 2024, 15:13 | Insight
Aggressive Lymphoma after CD19 CAR T-Cell Therapy suggested by Vivek Subbiah
Vivek Subbiah shared a post on X: "Aggressive Lymphoma after CD19 CAR T-Cell Therapy clonal hematopoiesis…
Aug 27, 2024, 17:43 | Insight
2nd trial for NET going into the world of CAR T-Cell
Lama Amer, Fellow at the University of Toronto, shared on X: "2nd trial for NET going…
Jul 24, 2024, 08:12 | Insight
Meta-analysis of non-relapse mortality post-CAR-T cells in lymphoma and myeloma
Nature Medicine shared on X about a paper titled "A systematic review and meta-analysis of nonrelapse…
Jun 18, 2024, 14:43 | Immune Oncology
CAR T Cell Therapy for Cancer Treatment
Introduction Chimeric antigen receptor - CAR T Cell therapy represents a groundbreaking approach in cancer…
Jun 11, 2024, 14:59 | Insight
Timos Papagatsias: EHA24 is expected to be one of the most exciting EHA conferences to-date!
Timos Papagatsias, CEO of LucidQuest shared a post on LinkedIn: “EHA24 is fast approaching and…
May 26, 2024, 11:34 | Insight
Krishna Komanduri: Congrats to Sattva Neelapu and colleagues for this correlative study on CAR-T cell fitness and function in lymphoma
Krishna Komanduri, Physician-in-Chief at the Helen Diller Family Comprehensive Cancer Center, shared a post by…
Apr 15, 2024, 02:29 | Insight
Evan Weber: Transcription factors that drive beneficial memory programs in CAR T cells
Evan Weber, Assistant Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine,…
Feb 21, 2024, 18:18 | Insight
Vivek Subbiah: As of December 31, 2023, the FDA had become aware of 22 cases of T-cell cancers that occurred after treatment with CAR-T products
Vivek Subbiah shared on LinkedIn: "Perspective article on 'Secondary Cancers after Chimeric Antigen Receptor T-Cell…
Feb 2, 2024, 05:57 | Blog
Mark Geyer: Tigen Pharma has formally agreed to partner with us in clinical development of our CAR T-cell product for AML
Mark Geyer, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, recently shared on X/Twitter:…
Jan 19, 2024, 17:40 | Opinion
Nishant Tiwari: Educational thread on hemophagocytic lymphohistiocytosis
Nishant Tiwari, Incoming Hematology-Oncology Fellow at OU Health Stephenson Cancer Centre, shared a thread on…
Jan 8, 2024, 15:01 | Blog
Li Tang: We discovered that IL-10-expressing CAR T-cells resist T cell dysfunction and mediate durable clearance of solid tumors and metastases
Li Tang, Associate Professor at the Swiss Federal Institute of Technology Lausanne (EPFL), shared a…
Nov 17, 2023, 17:20 | Blog
Giles Robinson: Loc3Car is the St. Jude Children’s Research Hospital's Brain Tumor Program’s first venture into Car T-Cell therapy
Giles Robinson, Neuro-Oncology Division Director at St. Jude Children’s Research Hospital, shared on X/Twitter: "Loc3Car…
Sep 25, 2023, 16:24 | Blog
Graham Collins: Reflections on being a new National Health Service (NHS) CAR T-cell centre.
Quoting Graham Collins, Associate Professor of Hematology at the Oxford Cancer and Hematology Center, on…
Jul 14, 2023, 06:48 | Opinion
At the recent European Hematology Association Congress in Frankfurt, I presented compelling findings from a proof of concept anti-BCMA CAR T-cell therapy study conducted at Sheba - Arnon Nagler
All: 14 Posts: 1 - 100
Special Coverage